Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of its initial public offering of 21,562,500 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 2,812,500 additional shares, at an initial public offering price of $16.00 per share. The aggregate gross proceeds from the offering were $345.0 million.
UCSF Researcher Kevan Shokat, PhD, is one of Erasca's lead contributing scientists.